$CTOR
CITIUS ONCOLOGY, INC.

2024 Q4 Form 10-K Financial Statement

#000121390024113150 Filed on December 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $4.925M
YoY Change 16.14%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $20.57M
YoY Change 1930.73%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $121.6K
YoY Change -96.46%
Pretax Income -$20.57M
YoY Change -950.36%
Income Tax $576.0K
% Of Pretax Income
Net Earnings -$21.15M
YoY Change -974.17%
Net Earnings / Revenue
Basic Earnings Per Share -$0.31
Diluted Earnings Per Share -$0.31
COMMON SHARES
Basic Shares Outstanding 71.55M shares 2.355M shares 68.05M shares
Diluted Shares Outstanding 68.05M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $112.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $8.269M
Prepaid Expenses $2.700M
Receivables
Other Receivables
Total Short-Term Assets $10.97M
YoY Change 12780.92%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $73.40M
YoY Change 3.92%
TOTAL ASSETS
Total Short-Term Assets $10.97M
Total Long-Term Assets $73.40M
Total Assets $84.37M
YoY Change 19.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.712M
YoY Change 187.94%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.70M
YoY Change 2698.31%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $32.70M
Total Long-Term Liabilities
Total Liabilities $38.23M
YoY Change 3171.37%
SHAREHOLDERS EQUITY
Retained Earnings -$39.28M
YoY Change 3524.86%
Common Stock $7.155K
YoY Change 4184.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.14M
YoY Change
Total Liabilities & Shareholders Equity $84.37M
YoY Change 19.31%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024
OPERATING ACTIVITIES
Net Income -$21.15M
YoY Change -974.17%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $126.4K
YoY Change -121.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.000M
YoY Change 278.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $4.874M
YoY Change 192.74%
NET CHANGE
Cash From Operating Activities $126.4K
Cash From Investing Activities -$5.000M
Cash From Financing Activities $4.874M
Net Change In Cash $112.00
YoY Change -100.04%
FREE CASH FLOW
Cash From Operating Activities $126.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
001-41534
CY2024 dei Entity Registrant Name
EntityRegistrantName
Citius Oncology, Inc.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-4362660
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
11 Commerce Drive
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
First Floor
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Cranford
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07016
CY2024 dei City Area Code
CityAreaCode
(908)
CY2024 dei Local Phone Number
LocalPhoneNumber
967-6677
CY2024 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024 dei Trading Symbol
TradingSymbol
CTOR
CY2024 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Public Float
EntityPublicFloat
47700000 usd
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71552402 shares
CY2024 cyd Cybersecurity Risk Management Processes Integrated Flag
CybersecurityRiskManagementProcessesIntegratedFlag
true
CY2024 cyd Cybersecurity Risk Management Third Party Engaged Flag
CybersecurityRiskManagementThirdPartyEngagedFlag
true
CY2024 cyd Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag
CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
false
CY2024 cyd Cybersecurity Risk Management Positions Or Committees Responsible Flag
CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
true
CY2024 cyd Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag
CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
true
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024 dei Auditor Firm
AuditorFirmId
392
CY2024 dei Auditor Name
AuditorName
Wolf & Company, P.C.
CY2024 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2024Q3 us-gaap Cash
Cash
112 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
8268766 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2700000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7734895 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
10968878 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
7734895 usd
CY2024Q3 tenk Inprocess Research And Development Noncurrent
InprocessResearchAndDevelopmentNoncurrent
73400000 usd
CY2023Q3 tenk Inprocess Research And Development Noncurrent
InprocessResearchAndDevelopmentNoncurrent
40000000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
73400000 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
40000000 usd
CY2024Q3 us-gaap Assets
Assets
84368878 usd
CY2023Q3 us-gaap Assets
Assets
47734895 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3711622 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1289045 usd
CY2024Q3 tenk License Payable
LicensePayable
28400000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
259071 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32700429 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21047235 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1728000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1152000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
38228540 usd
CY2023Q3 us-gaap Liabilities
Liabilities
22199235 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71552402 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71552402 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67500000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67500000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
7155 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6750 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85411771 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43658750 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39278587 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18129840 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
46140339 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
25535660 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84368878 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47734895 usd
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4925001 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4240451 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8148929 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5915290 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
7498817 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1965500 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
20572747 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
12121241 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20572747 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12121241 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
576000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
576000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21148747 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12697241 usd
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68053607 shares
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68053607 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67500000 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67500000 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
36267401 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1965500 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12697241 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
25535660 usd
CY2024 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
37008905 usd
CY2024 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7498817 usd
CY2024 tenk Merger Net Of Transactions Costs
MergerNetOfTransactionsCosts
2358780 usd
CY2024 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
2754296 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21148747 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
46140339 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21148747 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12697241 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
7498817 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1965500 usd
CY2024 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
576000 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
576000 usd
CY2024 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2133871 usd
CY2024 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1100000 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5044713 usd
CY2024 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2422577 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1196734 usd
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-259071 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-801754 usd
CY2024 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
14270648 usd
CY2023 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
14805474 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
126353 usd
CY2024 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5000000 usd
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000000 usd
CY2024 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
3827944 usd
CY2024 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
2754296 usd
CY2024 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3800111 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4873759 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
112 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112 usd
CY2024 tenk Ip Ramp D Milestones Included In License Payable
IPRampDMilestonesIncludedInLicensePayable
28400000 usd
CY2024 tenk Capital Contribution Of Due To Related Party By Parent
CapitalContributionOfDueToRelatedPartyByParent
33180961 usd
CY2024 tenk Prepaid Manufacturing Transferred To Inventory
PrepaidManufacturingTransferredToInventory
6134895 usd
CY2024 us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Oncology, Inc. (formerly Citius Acquisition Corp.) (“Citius Oncology,” the “Company” or “we”) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. We are developing E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma. We have obtained the trade name of LYMPHIR for E7777.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, and recruiting management and technical staff. Citius Oncology is subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by Citius Oncology or its competitors of research and development stage products, market acceptance of any of its products approved for marketing, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company’s ability to obtain additional financing and the Company’s compliance with governmental and other regulations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since its inception, Citius Pharmaceuticals, Inc. (“Citius Pharma”) has funded and continues to fund the Company. Citius Pharma and the Company are party to an amended and restated shared services agreement (the “A&amp;R Shared Services Agreement”), which governs certain management and scientific services that Citius Pharma provides the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Merger</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 23, 2021, Citius Pharma formed Citius Acquisition Corp. (“SpinCo”) as a wholly-owned subsidiary in conjunction with the acquisition of LYMPHIR, which began operations in April 2022, when Citius Pharma transferred the assets related to LYMPHIR to SpinCo, including the related license agreement and asset purchase agreement (see Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2023, Citius Pharma and SpinCo entered into an agreement and plan of merger and reorganization (the “Merger Agreement”) with TenX Keane Acquisition, a Cayman Islands exempted company (“TenX”), and TenX Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of TenX (“Merger Sub”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2024, pursuant to the terms and conditions of the Merger Agreement, Merger Sub merged with and into SpinCo, with SpinCo surviving as a wholly owned subsidiary of TenX (the “Merger”) which was subsequently renamed Citius Oncology Sub, Inc. Prior to closing of the Merger, TenX migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the General Corporation Law of the State of Delaware and the Cayman Islands Companies Act (As Revised) (the “Domestication”). As part of the Domestication, TenX changed its name to “Citius Oncology, Inc.” (Nasdaq: CTOR). Immediately after the closing of the Merger, Citius Pharma owned approximately 92.3% of the outstanding shares of common stock of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the Merger Sub was the legal acquirer of the Company, for accounting purposes, the Company was deemed to be the accounting acquirer. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing stock for the assets and liabilities of the Merger Sub, accompanied by a recapitalization. Total shares outstanding of the Company after the Merger and recapitalization increased to 71,552,402. The net assets of the merged entities are stated at historical cost, with no goodwill or other intangible assets recorded. Additionally, the historical financial statements of the Company became the historical financial statements of the Registrant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger, net amount of $2,753,795 charged to additional paid in capital consists of $395,015 of net liabilities of TenX on the date of the Merger (cash of $163,500 less liabilities of $559,015) plus directly related transaction costs of $2,358,780.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Merger, Citius Pharma made capital investments in the Company through cash contributions of $3,827,944 to fund transactions related to the Merger and by reclassifying to additional paid in capital intercompany receivables of $33,180,961 that were due from the Company to Citius Pharma. Simultaneously, Citius Pharma advanced an additional $3,800,111 to the Company under the terms of a note payable (see Note 6).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On July 5, 2023, the Company executed a stock split of its shares of common stock at a ratio of 675,000-for-1 (the “Stock Split”). All of the Company’s historical share and per share information related to issued and outstanding common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 675,000-for-1 stock split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the operations of Citius Oncology, Inc., and its wholly-owned subsidiary, Citius Oncology Sub, Inc., which was formed in connection with Merger. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </p>
CY2024Q3 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
71552402 shares
CY2024Q3 us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
2753795 usd
CY2024Q3 us-gaap Other Liabilities
OtherLiabilities
559015 usd
CY2024 tenk Related Transaction Costs
RelatedTransactionCosts
2358780 usd
CY2024 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
3827944 usd
CY2024 tenk Additional Paid In Capital Receivables
AdditionalPaidInCapitalReceivables
33180961 usd
CY2024 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3800111 usd
CY2023Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
675,000-for-1
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-21148747 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-12697241 usd
CY2024Q3 tenk Working Capital
WorkingCapital
21731551 usd
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development, stock-based compensation and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2700000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7734895 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6134895 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2133862 usd
CY2024 tenk Prepaid Manufacturing Transferred To Inventory
PrepaidManufacturingTransferredToInventory
6134895 usd
CY2024 tenk In Process Research And Development Amount
InProcessResearchAndDevelopmentAmount
73400000 usd
CY2024 tenk In Process Research And Development Initial Payments
InProcessResearchAndDevelopmentInitialPayments
40000000 usd
CY2024Q3 tenk License Payable
LicensePayable
28400000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P12Y
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.</p>
CY2024 tenk Development Milestone Payments
DevelopmentMilestonePayments
70000000 usd
CY2024 tenk Commercial Sales Milestones
CommercialSalesMilestones
300000000 usd
CY2024Q3 tenk Net Sales Percentage
NetSalesPercentage
0.50 pure
CY2024 tenk Net Product Sales Payment
NetProductSalesPayment
22000000 usd
CY2024 tenk Reimburse Amount
ReimburseAmount
2650000 usd
CY2024Q3 tenk Development Milestone Payments
DevelopmentMilestonePayments
33400000 usd
CY2024Q3 tenk License Payable Current
LicensePayableCurrent
5000000 usd
CY2024Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
33400000 usd
CY2023Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
110000000 shares
CY2023Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
675,000-for-1
CY2023Q3 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
100 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15000000 shares
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P10Y
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0466 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0411 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M15D
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.87 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.91 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12600000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.15
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y9M7D
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
150000 shares
CY2024 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.15
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12750000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.15
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M10D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3937500 shares
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.15
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M7D
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.66
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P10Y
CY2024 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7498817 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11592383 usd
CY2024 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M7D
CY2024 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1846202 usd
CY2024 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
1963630 usd
CY2024 us-gaap Other Expenses
OtherExpenses
121570 usd
CY2023 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1727595 usd
CY2023 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
1496401 usd
CY2023 us-gaap Other Expenses
OtherExpenses
121470 usd
CY2024 tenk Capital Contribution Of Due To Related Party By Parent
CapitalContributionOfDueToRelatedPartyByParent
33180961 usd
CY2024 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
3827944 usd
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
3800111 usd
CY2024 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000 usd
CY2024 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
576000 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
576000 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.21 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.071 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.071 pure
CY2024 tenk Permanent Differences
PermanentDifferences
0.061 pure
CY2023 tenk Permanent Differences
PermanentDifferences
0.026 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.248 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.303 pure
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.028 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.048 pure
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7530000 usd
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4646000 usd
CY2024Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2080000 usd
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1073000 usd
CY2024 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1091000 usd
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
239000 usd
CY2024Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1035000 usd
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
850000 usd
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-11736000 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-6808000 usd
CY2024Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1728000 usd
CY2023Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1152000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1728000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1152000 usd
CY2024Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1728000 usd
CY2023Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1152000 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4928000 usd
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4043000 usd
CY2024 tenk Federal Net Operating Loss Carryforward
FederalNetOperatingLossCarryforward
28700000 usd
CY2024 tenk Federal Research And Development
FederalResearchAndDevelopment
1035000 usd
CY2024 us-gaap Payments For Fees
PaymentsForFees
250000 usd
CY2024 us-gaap Production And Distribution Costs
ProductionAndDistributionCosts
17300000 usd
CY2024Q3 us-gaap Other Commitment
OtherCommitment
4500000 usd
CY2023Q3 us-gaap Cash
Cash
usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
usd
CY2023Q3 tenk License Payable
LicensePayable
usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024 us-gaap Revenues
Revenues
usd
CY2023 us-gaap Revenues
Revenues
usd
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
usd
CY2023 us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023 tenk Ip Ramp D Milestones Included In License Payable
IPRampDMilestonesIncludedInLicensePayable
usd
CY2023 tenk Capital Contribution Of Due To Related Party By Parent
CapitalContributionOfDueToRelatedPartyByParent
usd
CY2023 tenk Prepaid Manufacturing Transferred To Inventory
PrepaidManufacturingTransferredToInventory
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001851484

Files In Submission

Name View Source Status
0001213900-24-113150-index-headers.html Edgar Link pending
0001213900-24-113150-index.html Edgar Link pending
0001213900-24-113150.txt Edgar Link pending
0001213900-24-113150-xbrl.zip Edgar Link pending
ea0225372-10k_citius.htm Edgar Link pending
ea022537201ex10-3_citius.htm Edgar Link pending
ea022537201ex19-1_citius.htm Edgar Link pending
ea022537201ex31-1_citius.htm Edgar Link pending
ea0225372-10k_citius_htm.xml Edgar Link completed
ea022537201ex31-2_citius.htm Edgar Link pending
ea022537201ex32-1_citius.htm Edgar Link pending
ea022537201ex4-2_citius.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tenk-20240930.xsd Edgar Link pending
tenk-20240930_lab.xml Edgar Link unprocessable
tenk-20240930_cal.xml Edgar Link unprocessable
tenk-20240930_def.xml Edgar Link unprocessable
tenk-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable